COST-EFFECTIVENESS OF VEDOLIZUMAB COMPARED WITH CONVENTIONAL THERAPY IN PATIENTS WITH CROHN'S DISEASE IN THE UNITED KINGDOM (UK)

被引：0
|
作者：
Robson, R. E. [1 ]
Vanoli, A. [2 ]
Tolley, K. [3 ]
机构：
[1] Tolley Hlth Econ, Buxton, England
[2] CEMOR Med Ltd, Newcastle Upon Tyne, Tyne & Wear, England
[3] Tolley Hlth Econ Ltd, Buxton, England
来源：
VALUE IN HEALTH | 2018年 / 21卷
关键词：
D O I：
10.1016/j.jval.2018.09.2689
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PSY114
引用
收藏
页码：S455 / S456
页数：3
相关论文
共 50 条
  • [31] The effectiveness of ustekinumab and vedolizumab as third-line biologic therapy in patients with Crohn?s disease
    Macaluso, Fabio Salvatore
    Grova, Mauro
    Saladino, Marica
    Cappello, Maria
    Demarzo, Maria Giulia
    Privitera, Antonino Carlo
    Giangreco, Emiliano
    Garufi, Serena
    Renna, Sara
    Casa, Angelo
    Ventimiglia, Marco
    Fries, Walter
    Orlando, Ambrogio
    DIGESTIVE AND LIVER DISEASE, 2023, 55 (04) : 471 - 477
  • [32] The Effectiveness of Ustekinumab and Vedolizumab as Third-line Therapy in Patients with Refractory Crohn's Disease
    Macaluso, F. S.
    Grova, M.
    Saladino, M.
    Demarzo, M. G.
    Privitera, A. C.
    Giangreco, E.
    Garufi, S.
    Renna, S.
    Casa, A.
    Ventimiglia, M.
    Cappello, M.
    Fries, W.
    Orlando, A.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I359 - I359
  • [33] Cost-effectiveness of Prophylaxis Against Pneumocystisjiroveci Pneumonia in Patients with Crohn’s Disease
    Philip N. Okafor
    Francis A. Farraye
    Adetoro T. Okafor
    Daniel O. Erim
    Digestive Diseases and Sciences, 2015, 60 : 3743 - 3755
  • [34] COST-EFFECTIVENESS ANALYSIS OF USTEKINUMAB VERSUS ADALIMUMAB, INFLIXIMAB AND VEDOLIZUMAB FOR THE TREATMENT OF PATIENTS WITH MODERATELY TO SEVERE ACTIVE CROHN'S DISEASE FOR TURKEY
    Arhan, M.
    Tezel, H. A.
    Toruner, M.
    Bilaloglu, B.
    Koral, S.
    Ozer, E.
    VALUE IN HEALTH, 2018, 21 : S145 - S145
  • [35] THE EFFECTIVENESS OF USTEKINUMAB AND VEDOLIZUMAB AS THIRD-LINE THERAPY IN PATIENTS WITH REFRACTORY CROHN'S DISEASE
    Macaluso, F. S.
    Grova, M.
    Saladino, M.
    Demarzo, M. G.
    Privitera, A. C.
    Giangreco, E.
    Garufi, S.
    Renna, S.
    Casa, A.
    Ventimiglia, M.
    Cappello, M.
    Fries, W.
    Orlando, A.
    DIGESTIVE AND LIVER DISEASE, 2022, 54 : S93 - S94
  • [36] Efficacy of Vedolizumab Therapy in Patients With Perianal Crohn's Disease
    Manski, Scott
    Edirisuriya, Chelsea
    Fabrizio, Joseph
    Dioguardi, Vincent
    Gandhi, Hema K.
    Shivashankar, Raina
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S847 - S848
  • [37] Cost-Effectiveness of Pentostatin Compared With Cladribine in the Management of Hairy Cell Leukemia in the United Kingdom
    Guest, Julian F.
    Smith, Helen
    Sladkevicius, Erikas
    Jackson, Graham
    CLINICAL THERAPEUTICS, 2009, 31 : 2398 - 2415
  • [38] A cost-effectiveness analysis of endoscopic eradication therapy for management of dysplasia arising in patients with Barrett's oesophagus in the United Kingdom
    Pollit, Vicki
    Graham, David
    Leonard, Catherine
    Filby, Alexandra
    McMaster, Jessica
    Mealing, Stuart J.
    Lovat, Laurence B.
    Haidry, Rehan J.
    CURRENT MEDICAL RESEARCH AND OPINION, 2019, 35 (05) : 805 - 815
  • [39] COST-EFFECTIVENESS OF ADALIMUMAB FOR TREATMENT OF CROHN'S DISEASE IN GERMANY
    Yang, M.
    Yang, M.
    Skup, M.
    Zhou, Z. Y.
    Hengst, N.
    Wolff, M.
    Mulani, P. M.
    Chao, J.
    VALUE IN HEALTH, 2012, 15 (07) : A329 - A329
  • [40] Cost-effectiveness of natalizumab in patients with Crohn's disease who have failed Anti-TNFα therapy
    Sands, Bruce
    Wolf, Douglas
    Panjabi, Sumeet
    Niecko, Timothy
    Hass, Steven
    Lacey, Loretto
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2008, 103 : S401 - S402
12345